Search research articles
Contact Us
Filters
Showing results (31-40 of 36) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 36 results.
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 13, 2009
Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective
Roberta Ara, Rachid Rafia, Sue E Ward, et al.
Clinical Therapeutics
|
September 23, 2008
Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries
Roberta Ara, Abdullah Pandor, Indra Tumur, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
January 23, 2009
Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model
Roberta Ara, Abdullah Pandor, Indra Tumur, et al.
International Journal of Technology Assessment in Health Care
|
November 14, 2014
Are policy decisions on surgical procedures informed by robust economic evidence? A systematic review
Roberta Ara, Hasan Basarir, Anju D Keetharuth, et al.
Drugs
|
March 1, 2005
An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists
Nick J Bansback, Dean A Regier, Roberta Ara, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 6, 2019
Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report
John Brazier, Roberta Ara, Ismail Azzabi, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 36) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 36 results.
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 13, 2009
Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective
Roberta Ara, Rachid Rafia, Sue E Ward, et al.
Clinical Therapeutics
|
September 23, 2008
Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries
Roberta Ara, Abdullah Pandor, Indra Tumur, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
January 23, 2009
Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model
Roberta Ara, Abdullah Pandor, Indra Tumur, et al.
International Journal of Technology Assessment in Health Care
|
November 14, 2014
Are policy decisions on surgical procedures informed by robust economic evidence? A systematic review
Roberta Ara, Hasan Basarir, Anju D Keetharuth, et al.
Drugs
|
March 1, 2005
An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists
Nick J Bansback, Dean A Regier, Roberta Ara, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 6, 2019
Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report
John Brazier, Roberta Ara, Ismail Azzabi, et al.
Page
of 4